Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Liabilities and Shareholders Equity (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Liabilities and Shareholders Equity for 12 consecutive years, with $106.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 55.84% to $106.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $377.4 million, a 62.04% increase, with the full-year FY2025 number at $106.4 million, up 55.84% from a year prior.
  • Liabilities and Shareholders Equity was $106.4 million for Q4 2025 at Niagen Bioscience, up from $98.1 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $106.4 million in Q4 2025 to a low of $45.7 million in Q3 2022.
  • A 5-year average of $63.6 million and a median of $55.0 million in 2023 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: dropped 29.2% in 2022, then surged 73.63% in 2025.
  • Niagen Bioscience's Liabilities and Shareholders Equity stood at $57.8 million in 2021, then fell by 6.54% to $54.1 million in 2022, then grew by 1.68% to $55.0 million in 2023, then increased by 24.22% to $68.3 million in 2024, then skyrocketed by 55.84% to $106.4 million in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Liabilities and Shareholders Equity are $106.4 million (Q4 2025), $98.1 million (Q3 2025), and $91.5 million (Q2 2025).